#CTAD26: Lilly’s dopamine drug mevidalen fails Phase 2 study in Alzheimer’s
BOSTON — A little-known therapy Eli Lilly has quietly been testing in people with mild and moderate Alzheimer’s disease has failed in its Phase 2 study. The experimental drug, called mevidalen, was dropped ...
comments(0)
5-min edit window · permanent after that